- Open Access
Non-cysteine linked MUC1 cytoplasmic dimers are required for Src recruitment and ICAM-1 binding induced cell invasion
Molecular Cancervolume 10, Article number: 93 (2011)
The mucin MUC1, a type I transmembrane glycoprotein, is overexpressed in breast cancer and has been correlated with increased metastasis. We were the first to report binding between MUC1 and Intercellular adhesion molecule-1 (ICAM-1), which is expressed on stromal and endothelial cells throughout the migratory tract of a metastasizing breast cancer cell. Subsequently, we found that MUC1/ICAM-1 binding results in pro-migratory calcium oscillations, cytoskeletal reorganization, and simulated transendothelial migration. These events were found to involve Src kinase, a non-receptor tyrosine kinase also implicated in breast cancer initiation and progression. Here, we further investigated the mechanism of MUC1/ICAM-1 signalling, focusing on the role of MUC1 dimerization in Src recruitment and pro-metastatic signalling.
To assay MUC1 dimerization, we used a chemical crosslinker which allowed for the detection of dimers on SDS-PAGE. We then generated MUC1 constructs containing an engineered domain which allowed for manipulation of dimerization status through the addition of ligands to the engineered domain. Following manipulation of dimerization, we immunoprecipitated MUC1 to investigate recruitment of Src, or assayed for our previously observed ICAM-1 binding induced events. To investigate the nature of MUC1 dimers, we used both non-reducing SDS-PAGE and generated a mutant construct lacking cysteine residues.
We first demonstrate that the previously observed MUC1/ICAM-1signalling events are dependent on the activity of Src kinase. We then report that MUC1 forms constitutive cytoplasmic domain dimers which are necessary for Src recruitment, ICAM-1 induced calcium oscillations and simulated transendothelial migration. The dimers are not covalently linked constitutively or following ICAM-1 binding. In contrast to previously published reports, we found that membrane proximal cysteine residues were not involved in dimerization or ICAM-1 induced signalling.
Our data implicates non-cysteine linked MUC1 dimerization in cell signalling pathways required for cancer cell migration.
The ability of malignant cells to escape from a primary tumour mass and migrate to distal sites to form metastatic tumors is the cause of mortality in the majority of carcinomas, including breast carcinoma. Approximately 20% of breast cancers belong to the Luminal B genetic subtype, typified by estrogen receptor positivity and a slow, steady rate of recurrence over time despite anti-estrogen therapy . Estrogen is known to increase the expression of MUC1 , a well-characterized member of the mucin family of glycoproteins, and a correlation has been demonstrated between MUC1 expression, resistance to anti-estrogen therapy and metastatic behaviour . We have been investigating the mechanism of cell migration in the Luminal B breast cancer cell lines MCF7 and T47D, and were the first to demonstrate that MUC1 mediates heterotypic cell-cell adhesion by binding ICAM-1 , which is expressed on peritumoral stromal and endothelial cells. Subsequently, we demonstrated that ICAM-1 binding triggers calcium oscillations which may activate proteins involved in focal adhesion disassembly and cell contraction. In keeping with this, we further reported that after interaction with ICAM-1, transendothelial migration invasion in MUC1 expressing cells is associated with increased MUC1-Src association, MUC1-cytoplasmic domain (MUC1-CD) phosphorylation, CrkL recruitment, and Rho-GTPase mediated cytoskeletal rearrangement [5–7].
MUC1 (also known as DF3, CA15-3, or episialin) is expressed apically on normal breast epithelia, but often loses this polarization and becomes underglycosylated in breast cancer [8, 9]. MUC1 is translated as a single polypeptide, followed by conformational stress-induced cleavage resulting in a heterodimer of non-covalently associated extracellular and cytoplasmic portions [10, 11] (Figure 1). The extracellular portion consists of a variable number of 20-amino acid (aa) tandem repeats containing multiple sites for O-glycosylation, which impart a negative charge and result in a structure that can extend up to 500 nm from the cell surface. The cytoplasmic portion consists of a 58-aa extracellular stub, a 28-aa transmembrane domain, and a 72-aa cytoplasmic domain, which contains seven conserved tyrosine residues, and has been shown to interact with diverse effectors [Reviewed in ] which is important since MUC1-CD itself lacks tyrosine kinase activity.
The signalling capacity of transmembrane proteins lacking kinase activity is often mediated by associated non-receptor tyrosine kinases. In some instances, these kinases are bound to pre-formed dimers of the receptor [, Reviewed in ]. Upon ligand binding, structural changes such as cysteine linkage, association with detergent resistant membrane fractions, and changes in cleavage result in signal initiation [15–17]. Previous work by others has demonstrated that constructs of the MUC1-CD form oligomers in vitro which are disulfide-linked, and in vivo which are dependent on the membrane-proximal cytoplasmic C1QC motif [18, 19] (Figure 1). Here, we investigated dimer formation in wild-type MUC1 and the relationship between dimerization, Src recruitment and ICAM-1 induced signalling events. We also examined the role of membrane-proximal cytoplasmic domain cysteine residues in these phenomena. We confirm that Src is an essential mediator of the previously observed ICAM-1 binding pro-motility events and show that MUC1 forms constitutive cytoplasmic domain dimers which are required for constitutive Src recruitment and ICAM-1 binding induced signalling. Contrary to previous reports, we found that dimers are not disulfide linked constitutively or following ICAM-1 ligation, and that membrane-proximal cysteine residues are not required for dimerization or ICAM-1 induced events.
Materials and methods
Antibodies and Reagents
CT2 Armenian Hamster monoclonal antibody (mAb) , directed against the last 17 C-terminal amino acids of MUC1-CD, was generously provided by Dr. Sandra Gendler (Mayo Clinic, Scottsdale, AZ). Rabbit anti-Src mAb, anti-SrcP416 polyclonal Abs, and anti-rabbit peroxidase conjugated secondary antibody were purchased from Cell Signalling. Goat anti-mouse and anti-Armenian hamster peroxidase-conjugated secondary antibodies were purchased from Jackson ImmunoResearch Laboratories, Inc. Mouse anti-tubulin antibody was from Sigma-Aldrich. Disuccinimidyl suberate (DSS) was from PierceNet. Protein G-Agarose was purchased from Roche Diagnostics. ECL Plus Western Blotting detection reagent was purchased from GE Healthcare (Amersham Biosciences). Gelatin Type A and phosphatase inhibitor cocktail were from Sigma-Aldrich. Protease inhibitor cocktail was from Calbiochem. Dulbecco's modified eagle media (DMEM), fetal bovine serum (FBS), Lipofectamine 2000, G418, Blasticidin S HCl, Pluronic F-127, Fluo-3 and Cell Tracker Green CMFDA were from Invitrogen. AP20187D and AP21998M were generous gifts from ARIAD Pharmaceuticals, Inc (Cambridge, MA, USA).
The pC1-Neo-hMUC1-TR+ plasmid was kindly provided by Dr. Sandra Gendler. The pUC-CVM-MUCY plasmid was from Gene-Therapeutics Luckenwalde (Luckenwalde, Germany). MUC1-CFP and MUCY-YFP were constructed by inserting the MUC1/MUCY genes into pECFP/pEYFP plasmids (ClonTech) respectively, at XhoI and SacII sites. The plasmid pC4-Fv1E encoding the FKBP F36V variant followed by a c-terminal hemagglutinin (HA) epitope was generously provided by ARIAD Pharmaceuticals Inc. To generate the MUC1-CFP-FvHA and MUCY-YFP-FvHA fusion proteins, the FvHA domain of pC4-Fv1E was amplified by polymerase chain reaction (PCR) with a 5' primer (ATTTGTACA TGGCTTCTAGAGGAGTGC) and a 3' primer (CTCTTGTACA CTGAAGTTCTCAGGATCC) which introduced 3' and 5' BsrG1 restriction sites (underlined). The PCR product and MUC1-CFP/MUCY-YFP plasmids were digested with BsrG1, ligated, and sequenced to confirm insertion and orientation. MUC1-CFP-FvHA (CQC to AQA) was constructed by PCR of MUC1-CFP using overlapping forward (TTGGCTGTCGCT CAGGCC CGCCGAAAG) and reverse (CTTTCGGC GGGCCTGAGC GACAGCCAA) primers to generate the mutation (underlined) and upstream (GGCACCTCTGCCAGG GCTACCACAACC) and downstream (GACCGGTGGATCC CGGGCCCG) primers containing EcoN1 and BamH1 restriction sites, respectively (underlined). Digestion of plasmid and PCR product with EcoN1 and BamH1 was followed by ligation of the plasmid backbone and mutated insert and sequencing to confirm insert. The pcDNA3.1-CD8/MUC1 plasmid was kindly provided by Dr. K.C. Kim (Lovelace Respiratory Research Institute, AZ), and encodes a construct containing the extracellular and transmembrane portions of cluster of differentiation 8 (CD8) and MUC1-CD, beginning at R4RK (Figure 1).
Human breast cancer cell lines T47D and MCF-7 were from the American Type Culture Collection (ATCC) and were maintained in DMEM with 10% FBS and 6 ug/ml insulin. 293T human embryonic kidney epithelial cells (293T HEK) were from ATCC and maintained in DMEM with 10% FBS. Mock and ICAM-1 transfected NIH 3T3 mouse fibroblast cells were a generous gift of Dr. Ken Dimock (University of Ottawa, Ontario, Canada) and were maintained in DMEM with 10% FBS and 5 ug/ml Blasticidin S. HEK 293T cells transfected with MUC1 constructs were maintained in DMEM with 10% FBS and 200 ug/ml G418 and used for experiments within 48 hours of transfection. Cell lines have not been further tested or authenticated.
Small interfering ribonucleic acid (siRNA) knockdown
4 × 105 HEK 293T cells were plated in a 6-well plate and allowed to adhere overnight to approximately 50% confluency. siRNA (Dharmacon) consisted of four pooled siRNA species targeting the following Src sequences: GCAGUUGUAUGCUGUGGUU, GCAGAGAACCCGA GAGGGA, CCAAGGGCCUCA ACGUGAA, and GGGAGAACCUCUAGGCACA. Transfection was performed using Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. Lipofectamine reagent only or non-targeting siRNA were used as negative controls.
To detect constitutive dimers, we added a cross-linking agent before lysis to parallel cultures and analyzed by Western blot as follows. 3 × 106 human breast cancer cells or transfected HEK 293T cells were plated on 0.1% gelatin coated, UV-treated 10 cm dishes and allowed to adhere overnight. Cells were then serum starved for 45 minutes in Imaging Buffer (152 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl2 6H2O, 1.8 mM CaCl2 2H2O, 10 mM HEPES, 5.6 mM D-glucose). Treatment compounds or cell suspensions were then added as indicated, in 37°C Imaging buffer, followed by 1 mM DSS in ice-cold PBS for 10 minutes. DSS is a membrane-permeable, permanent crosslinker which targets primary amine residues (lysines) within 11.4 Å of eachother. DSS does not induce dimerization of lysine-containing proteins, but rather aids in identification of protein complexes which are already formed upon treatment. DSS was aspirated, cells resuspended in quenching solution (1M Tris, pH 7.5) and centrifuged. The pellet was suspended in ice-cold lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% glycerol, 1% Triton X-100, 0.5% phosphatase and protease inhibitors) or Co-immunoprecipitation lysis buffer (50 mM Tris pH 7.6, 100 mM NaCl, 0.5 mM EDTA, 0.5% Nonidet P-40, 0.5% protease and phosphatase inhibitors). Lysates were immunoprecipitated with CT2 and/or prepared for Western blot analysis as described below.
To artificially manipulate MUC1-CD dimerization we used the "ARGENT™ Regulated homodimerization kit" and the "RPD™ Regulated secretion/aggregation kit" (Ariad Pharmacauticals, Inc.). The kits were designed to manipulate protein dimerization status by interacting an engineered "Fv dimerization domain" with monovalent and bivalent ligands. The "Fv domain" is a mutant of the naturally occurring FK506 binding protein (FKBP) with a F36V mutation introduced to prevent binding of Fv ligands to endogenous FKBP. A MUC1-CFP-Fv construct was creating using this plasmid, as described above. Importantly, the Fv domain itself does not induce dimerization, and addition of Fv domain ligands is required to manipulate dimerization status of Fv domain containing proteins. The bivalent Fv ligand AP20187D was designed to induce dimerization of Fv domain containing proteins, while the monovalent Fv ligand AP21998M was designed to disaggregate existing dimers.
Immunoprecipitation and Western blots
Lysates were immunoprecipitated, prepared for SDS-PAGE, and probed for proteins of interest as described in . Films were scanned with a Canon Canoscan 8600F, imported into Image J (NIH), contrast and brightness adjusted and cropped for presentation.
Calcium oscillation assay
Calcium oscillation assay was performed and analyzed as described . Modifications included the treatment of cells with 1 uM AP21998M or AP20187D for 1 minute prior to addition of NIH ICAM-1 cells, and the use of Eclipse software to obtain digital interference contrast (DIC) and fluorescent images.
Transwell migration assay
The upper membrane of Transwell inserts (Corning Costar, 6.5 mm diameter, 8 μm pore size) coated with 0.1% gelatin and 200 ul of ICAM-1/mock cell suspension at 1.5 × 105 cells/ml was placed in a 24-well plate and allowed to adhere overnight at 37°C. 293T MUC1 transfectants were suspended in 5 uM Cell tracker green in serum-free DMEM for 30 minutes at 37°C, followed by incubation in serum free DMEM at 37°C for 30 minutes. Cells were spun and suspended in serum-free media at 8 × 105 cells/ml. 1 uM AP21998M or AP20187D was added and 200 ul of cell suspension was added to the upper membrane of Transwell inserts. Fresh serum-free DMEM was added to the lower chamber. Following incubation at 37°C overnight, media was removed and 2% paraformaldehyde in PBS was added to each chamber for 15 minutes. Cells were washed twice with PBS, and cells on the upper membrane of the insert were removed with a sterile cotton swab. The insert was then placed under a Zeiss Axioscope Digital Imaging Microscope and cells on the lower side of the chamber were counted under a fluorescein isothiocyanate filter and 20× objective for five distinct fields of view.
All experiments were performed at least three times to allow for statistical analysis. The Newman-Keuls multiple range comparison was used to determine statistical differences in data sets with more than two experimental conditions. For pairwise comparisons, the Student's t test was used. P values are indicated for each analysis. For each experiment, pairs in the data set which are statistically different, or populations which do not overlap with any other in the data set, (p < 0.05) are indicated with an asterisk (*).
MUC1/ICAM-1 binding induced signalling is mediated by Src kinase
We first confirmed that Src kinase is a critical component of the MUC1/ICAM-1 signalling axis by siRNA knockdown of Src in MUC1-CFP transfected HEK 293T cells. After Src siRNA treatment, we obtained a ~50% reduction in the levels of Src protein, compared to treatment with Lipofectamine alone or scrambled siRNA (Figure 2a). We then assayed for calcium oscillations (Figure 2b) and migration (Figure 2c), and found that MUC1-CFP cells treated with Lipofectamine-only respond to ICAM-1 stimulation by generating calcium oscillations (Figure 2b) and cell migration (Figure 2c), indicating that the presence of the CFP tail does not interfere with this response. Non-transfected HEK 293T cells which have no MUC1 showed no difference in ICAM-1 binding induced calcium oscillations or migration with decreased Src. Addition of scrambled siRNA to the transfected MUC1-CFP cells showed no decrease in Src levels and levels of ICAM-1 binding induced events equivalent to the Lipofectamine-only condition (negative control). However, Src siRNA induced Src knockdown in HEK 293T cells transfected with MUC1-CFP resulted in significant decreases in the ICAM-1 binding initiated calcium oscillations (Figure 2b) and transmigration through an ICAM-1 monolayer (Figure 2c). This establishs Src kinase as an essential mediator of MUC1/ICAM-1 binding signalling and migration.
MUC1 forms constitutive cytoplasmic domain dimers in human breast cancer cell lines and transfected HEK 293T cells
MUC1 positive human breast cancer cell lines MCF-7 and T47D (Figure 3a) and HEK 293T cells transfected with MUC1-CFP (Figure 3b, panel 1) or the MUC1 splice variant lacking the tandem repeat domain MUCY-YFP-Fv (Figure 3b, panel 2) were lysed with or without prior treatment with the membrane permeable crosslinker DSS. No Fv ligands were added, so only constitutive dimers of the MUCY-YFP-Fv are detectable. DSS reacts with primary amine containing amino acids within 11.4Å distance to produce covalently bonded complexes. It is important to note that DSS only reacts with lysine residues which are within 11.4 Å of each other prior to DSS treatment; DSS itself does not induce complex formation. MUC1-CD contains a membrane-proximal lysine residue (R4RK) which would be susceptible to DSS crosslinking. Western blotting and probing for MUC1-CD in the cells treated with DSS revealed the invariable appearance of a new species at exactly double the molecular weight of the monomeric cytoplasmic domain, consistent with the presence of a MUC1-CD homodimer. The appearance of MUC1-CD dimers in MUCY-YFP-Fv transfectants indicates that the tandem repeat domain is not responsible for dimerization. This is not surprising due to the heavy glycosylation and negative charge of the tandem repeats. We then investigated the contribution of the MUC1 cytoplasmic domain to dimer formation. HEK 293T cells were co-transfected with MUCY-YFP-Fv and/or CD8/MUC1 , a chimera of CD8 extracellular and transmembrane domains and MUC1-CD domain, beginning at R4RK (Figure 1). Whole cell lysate of CD8/MUC1 (Figure 3c, lane 1) shows that this construct appears as a doublet at approximately 40 kDa in agreement with a publication describing this construct . MUCY-YFP-Fv runs at approximately 75 kDa (Figure 3c, lane 2), with another species migrating at approximately 45 kDa. This species could be the result of cleavage of the YFP-Fv tag prior to cell lysis, as MUCY is expected to migrate at this molecular weight. Dual transfection of CD8/MUC1 and MUCY-YFP-Fv demonstrates that both these constructs run at the expected molecular weights when co-expressed (Figure 3c, lane 3). Immunoprecipitation of double transfectants with anti-CD8 resulted in the appearance of MUCY-YFP-Fv on a Western blot (Figure 3c, lane 4), indicating an association between CD8/MUC1 and MUCY-YFP-Fv. This association is significant because the CD8/MUC1 construct only contains the cytoplasmic portion of MUC1, beginning at R4RK and does not contain the membrane proximal C1QC motif, fluorescent tags or an Fv domain. Therefore association between these two entities must be due to the MUC1 cytoplasmic domain. "Protein G + Antibody" and "Antibody only" lanes are included to identify non-specific immunoglobulin bands. Taken together, these data indicate that the cytoplasmic domain of MUC1 self-associates to form a constitutive homodimer.
MUC1-CD dimerization is independent of membrane-proximal cysteine residues
Previous publications investigating MUC1 dimerization have concluded that the membrane-proximal CQC motif is responsible for disulfide-linked oligomerization, which results in targeting of MUC1 to the nucleus , and MUC1 mediated resistance to oxidative stress [19, 22, 23]. Since the CD8/MUC1-MUCY co-immunoprecipitation experiments (Figure 3c) found MUC1-CD association in the absence of a CQC motif in the CD8/MUC1 partner, we sought to determine if CQC mediated dimerization was necessary for our observed constitutive MUC1 dimers in MUC1 full-length transfectants and breast cancer cell lines. Using non-reducing conditions, which would preserve any disulfide linkages in Western blotting, there were no bands at a molecular weight of presumed dimers in 293T MUC1-CFP or MCF-7 cells (Figure 4a). This suggests that MUC1-CD dimers are not disulfide linked. We confirmed this by mutating both cysteines in the native MUC1-CD CQC motif to alanines (AQA) and then assaying for dimers after DSS cross-linking. Note that no Fv ligands were added so that any dimers detected represent constitutive or pre-formed dimers. We found that the 293T MUC1-CFP-Fv (AQA) mutant formed cytoplasmic domain dimers (Figure 4b). The presence of DSS-stabilized dimers in the absence of Fv ligands indicates that constitutive MUC1-CD dimers form even when both cysteines are absent and constitutes conclusive proof that cellular MUC1-CD dimers are not disulfide linked.
MUC1 cytoplasmic domain dimerization can be disrupted by an engineered Fv domain and a monomeric ligand
To investigate the importance of MUC1 dimerization in Src association and ICAM-1 induced signalling, we manipulated dimerization using a chimeric construct of MUC1 and a C-terminal Fv domain (ARIAD Pharmaceuticals), which is FKBP (FK506 binding protein) with a F36V mutation, allowing for specific interaction between the engineered Fv domain and bivalent (AP20187D) or monovalent (AP21998M) ligands. Importantly, the Fv domain itself does not facilitate dimerization of proteins, but following addition of Fv domain ligands, dimerization status can be manipulated. Previously, this system has been used to successfully manipulate dimerization of growth factor receptors  and G protein-coupled receptors . Mechanistically, the bivalent ligand, which contains two Fv-binding domains, effectively brings two Fv-domain containing proteins within close proximity - "dimerization". The monovalent ligand, which contains one Fv-domain binding domain, is designed to bind to Fv-domain containing proteins and sterically inhibit their interaction with other proteins - "disaggregation" or "monomerization" (Figure 5a). MUC1-CD dimers were stabilized after Fv ligand treatment by addition of the DSS cross-linker prior to cell lysis. We found that treatment of 293T MUC1-CFP-Fv cells for one minute with increasing concentrations of AP20187D did not increase the quantity of MUC1-CD dimers above no treatment, while AP21998M treatment resulted in a dose dependant reduction in MUC1-CD dimerization (Figure 5b). After treatment with 1 μM of monomerizing Fv ligand, AP21998M there was a 60% reduction in detectable MUC1-CD dimers (Figure 5c). As a control, 293T MUC1-CFP cells, which lack the Fv domain, do not show a change in dimer quantity following treatment with AP20187D or AP21998M (Figure 5d). Densitometric analysis of the MUC1-CFP dimer band normalized to monomer band illustrates this observation further (Figure 5e).
MUC1-CD dimer disruption results in decreased recruitment of total and active Src kinase
To determine the importance of MUC1-CD dimerization in constitutive Src recruitment, 293T MUC1-CFP-Fv (Figure 6a, b), and, as a control, 293T MUC1-CFP (Figure 6c, d) cells were treated with increasing concentrations of AP20187D or AP21998M for one minute and immunoprecipitated with anti-MUC1-CD. Following separation on SDS-PAGE, blots were probed with anti-Src (total) and anti-SrcP416 (active). In the MUC1-CFP-Fv transfectants, the amount of total and active Src associated with MUC1-CD decreases in a dose-dependent manner with AP21998M treatment (Figure 6b, arrows). Treatment with AP20187D did not result in a significant change, and 293T MUC1-CFP cells were unaffected by Fv ligand treatment.
Densitometric analysis of Src and SrcP416 compared to MUC1-CD are given in Additional File 1. These data suggest that MUC1-CD dimers, but not monomers, contain a recruitment, and potentially an activation, motif for Src kinase.
MUC1-CD dimer disruption results in decreased ICAM-1 binding induced calcium oscillations and cell invasion
To determine if MUC1-CD dimerization is important in previously observed ICAM-1 binding induced events, we assayed parental (293T), 293T MUC1-CFP, and 293T MUC1-CFP-Fv, and 293T MUC1-CFP-Fv (AQA) cells for ICAM-1 binding induced calcium oscillations, and invasion through an ICAM-1 positive monolayer after addition of the Fv ligands 1 μM AP20187D or 1 μM AP21998M and compared this to a no treatment control. 293T MUC1-CFP and 293T MUC1-CFP-Fv cells responded to treatment with ICAM-1 positive cells, in the "no treatment" condition, by initiating calcium oscillations (Figure 7a) and increased invasion (Figure 7b) at levels which were significantly increased compared to Mock treatment and statistically equivalent, demonstrating that the addition of the CFP or CFP-Fv tag on the C-terminus did not affect MUC1 receptor response to ICAM-1 stimulation. The 293T MUC1-CFP-Fv (AQA) mutant also exhibited ICAM-1 binding induced calcium oscillations (Figure 8a) and cell invasion (Figure 8b) equivalent to the native 293T MUC1-CFP-Fv cells indicating that the CQC motif is not required for ICAM-1 induced signalling events. However, ICAM-1 binding induced calcium oscillations (Figure 7a) and invasion (Figure 7b) in 293T MUC1-CFP-Fv cells was significantly reduced by treatment with AP21998M, while prolonged treatment with AP20187D resulted in a significant increase in cell migration in 293T MUC1-CFP-Fv cells (Figure 7b). These data indicate that MUC1-CD dimerization is required for ICAM-1 binding induced events. Addition of the Fv ligands had no significant effect on the 293T MUC1-CFP transfectants lacking the Fv domain. As previous reports  have demonstrated that disruption of dimerization using peptides results in cell death, we performed a trypan blue exclusion assay after treatment with 1 μM AP20187D or AP21998M and saw no significant reduction in viability up to 72 hour exposure (See Additional File 2).
ICAM-1 ligation does not result in increased MUC1-CD dimerization or disulfide linkage of MUC1-CD dimers
Next, we investigated if ICAM-1 ligation results in a quantitative increase in MUC1 dimerization, a potential mechanism for signal initiation. T47D and 293T MUC1-CFP cells were treated with ICAM-1 transfected NIH 3T3 cells for 10 or 60 seconds prior to DSS treatment. These time points were chosen because previous work has demonstrated that increased Src and CrkL recruitment, MUC1-CD phosphorylation  and calcium oscillations  occur within one minute of ICAM-1 ligation. We found that ICAM-1 ligation did not increase the quantity of MUC1-CD dimer detected (Figure 9a), suggesting that a qualitative, rather than quantitative, change in MUC1-CD dimers is responsible for ICAM-1 induced signalling. We then considered the possibility that ICAM-1 binding triggers disulfide bridge formation, akin to growth hormone binding to pre-formed growth hormone receptor dimers , but were not able to detect MUC1-CD dimers in MCF-7 or 293T-MUC1-CFP cells subjected to reducing or non-reducing conditions after ICAM-1 treatment for 60 seconds (Figure 9b). As a control, the CD8/MUC1 chimera, which is disulfide linked via the CD8 extracellular region [26, 27], was run under reducing and non-reducing conditions. The appearance of a disulfide-linked dimer under non-reducing conditions (Figure 9c) validates our methods.
The MUC1 glycoprotein has been implicated in multiple tumorigenic processes including tumour formation, proliferation, and survival [19, 22, 28, 29]. We are unique in investigating the role of MUC1 in the motility of Luminal B breast cancer cell lines, focusing on the binding of MUC1 to ICAM-1. ICAM-1 is expressed throughout the migratory track of a metastasizing breast cancer cell and its role in leukocyte extravasation is well characterized [30, 31]. Although we have previously shown that MUC1/ICAM-1 ligation induces pro-motility behaviour [5–7], the mechanism of signal initiation was unknown. In this report, we show that dimerization of the MUC1-CD is essential for the ICAM-1 induced events and that this effect is most likely mediated through enhanced Src binding.
The signalling capacity of transmembrane proteins lacking kinase activity is often mediated by associated non-receptor tyrosine kinases. Here we show that Src kinase is essential for transmission of the migration related MUC1/ICAM-1 signal. This is consistent with the literature on Src inhibition in breast cancer. Even though transfection of Src alone does not have transforming ability , over activity of Src is commonly associated with breast tumour progression  and it has become a prime target for selective small molecule inhibitors: Dasatinib (Bristol-Myers Squibb), Bosutinib (Wyeth) and Saracatinib (AstraZeneca). Others have published that the MCF-7 luminal B cell line used in this study shows decreased migration when Src is inhibited [34–36]. This decrease in Src mediated cell migration is synergistic with concomitant Tamoxifen , associated with upregulation and stabilization of E- cadherin/β-catenin mediated intercellular adhesion [36, 38], and decreased activity of the integrin associated kinase, focal adhesion kinase (FAK) [34, 37]. These observations are consistent with MUC1 involvement in the observed Src motility pathway. Tamoxifen decreases MUC1 expression [39, 40] and down-regulation of MUC1 is associated with increased E-cadherin/β-catenin complex formation . Further, MUC1 has been shown to bind to FAK, possibly transporting Src to FAK forming a MUC1-Src-FAK complex, and increasing FAK activation . Thus the additive effect of Tamoxifen, the stabilization of intercellular adhesions and the decreased FAK activity are logical consequences of the dual inhibition of MUC1 and Src in the same pathway.
The association between MUC1 and Src is dependent on the existence of MUC1-CD dimers, indicating that MUC1-CD dimers adopt a conformation that is permissive Src binding. We have definitive (unpublished) data demonstrating that a Src-SH3 peptide binds to MUC1 constitutively via the putative SH3 binding domain R34XXP37P38XXXXR43. Binding of the Src SH3 domain has been previously described as a mechanism for partial unfolding of the inactive Src enzyme and can be associated with Src activation  suggesting a mechanism for MUC1-CD dimer activation of Src. In this regard, it is significant that Src-P416, which is indicative of fully active Src, also selectively binds to MUC1-CD dimers.
Classically, it was believed that surface membrane receptors existed as monomers until ligand binding induced dimerization of the receptors, allowing trans-activation of receptor associated kinases and the triggering of signal initiating phosphorylation cascades. In recent years, a new paradigm, typified by the growth hormone receptor (GHR), has emerged in which receptors exist as pre-formed ligand-independent dimers [, Reviewed in ]. Upon ligand binding to the dimers, structural changes such as cysteine linkage, association with detergent resistant membrane fractions or changes in receptor cleavage result in signal initiation [15–17]. We report here that the MUC1 cytoplasmic domain exists constitutively as a non-covalently linked dimer. We present evidence that in the absence of the transmembrane and extracellular domains, the cytoplasmic domain of MUC1 self-associates in a non-cysteine dependent fashion. It has been proposed that a "self-aggregation domain" exists in the extracellular stub of MUC1-CD , but further studies are required to address the possibility that functional dimerization in vivo involves several domains.
In this study, membrane proximal cysteine residues are not required for dimerization of MUC1-CD, Src recruitment, or ICAM-1 induced signalling indicating that disulfide bridge formation is not the ligand-induced signal initiating event, as has been proposed for GHR. This is to be expected since, in the reducing environment of the cytosol, formation and maintenance of disulfide bonds is unfavourable unless the redox balance is disrupted . Thus, disulfide linkage of MUC1 dimers reported by others [18, 19], represents an alternative functional pathway for MUC1-CD dimers, perhaps as a redox "sensor" [Reviewed in ], that is unrelated to the ICAM-1/Src motility pathway in the present study. In this way, cysteine-mediated dimerization of MUC1 in response to oxidative stress, could initiate a signalling cascade resulting in the demonstrated nuclear entry and expression of anti-oxidant enzymes ascribed to cysteine-linked MUC1-CD dimers [19, 22, 23].
Rational drug combination has received considerable interest in recent years [Reviewed in ] as it provides the opportunity for specific, synergistic inhibition of cell signalling pathways. Initial clinical results using Src inhibitors as single agents has shown them to be well-tolerated but have minimal anti-tumour response in patients . Several Src inhibitors are currently undergoing testing in clinical trials for use in breast cancer treatment alone and in combination with other inhibitors [Reviewed in ]. The subset of luminal B cancers with active Src kinase pathway  may be the ideal target for a combined Tamoxifen and anti-Src therapy. Our studies suggest that if these could be combined with an inhibitor of MUC1 dimerization that cell migration and metastases may be significantly decreased, possibly without the toxic effects of classic chemotherapy.
The MUC1 protein is overexpressed in the majority of breast cancers and is implicated in breast cancer metastasis. We show here for the first time that MUC1-CD forms non-covalently linked dimers which are required for recruitment of Src kinase, and ICAM-1 induced pro-metastatic events. This is significant because ICAM-1 is expressed throughout the migratory tract of a metastasizing breast cancer cell. Ligation of MUC1 and ICAM-1 may represent a mechanism for movement of breast cancer cells through stromal and endothelial tissues. Therefore, elucidation of the mechanism of MUC1/ICAM-1 signalling will reveal potential targets for anti-metastatic therapies. Our study sheds light on this mechanism and also demonstrates the need for additional research to resolve discrepancies in the field.
American tissue culture collection
cluster of differentiation 8
digital interference contrast
- Dulbecco's modified eagle media
focal adhesion kinase
fetal bovine serum
FK506 binding protein
growth hormone receptor
human embryonic kidney
Intercellular adhesion molecule-1
Mucin-1 cytoplasmic domain
phosphate buffered saline
polymerase chain reaction
-Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
small interfering ribonucleic acid.
Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009, 27: 1168-76. 10.1200/JCO.2008.18.1024
Zaretsky JZ, Barnea I, Aylon Y, Gorivodsky M, Wreschner DH, Keydar I: MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERalpha) in regulation of the MUC1 gene expression. Mol Cancer. 2006, 5: 57- 10.1186/1476-4598-5-57
Pitroda SP, Khodarev NN, Beckett MA, Kufe D, Weichselbaum RR: MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci USA. 2009, 106: 5837-41. 10.1073/pnas.0812029106
Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC: The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res. 1996, 56: 4244-9.
Rahn JJ, Shen Q, Mah BK, Hugh JC: MUC1 initiates a calcium signal after ligation by intercellular adhesion molecule-1. J Biol Chem. 2004, 279: 29386-90. 10.1074/jbc.C400010200
Shen Q, Rahn JJ, Zhang J, Gunasekera N, Sun X, Shaw A, Hendzel MJ, Hoffman P, Bernier A, Hugh JC: MUC1 initiates Src-CrkL-Rac1/Cdc42-mediated actin cytoskeletal protrusive motility after ligating intercellular adhesion molecule-1. Mol Cancer Res. 2008, 6: 555-67. 10.1158/1541-7786.MCR-07-2033
Rahn JJ, Chow JW, Horne GJ, Mah B, Emerman J, Hoffman P, Hugh JC: MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis. 2005, 22: 475-83. 10.1007/s10585-005-3098-x
Rahn J, Dabbagh L, Pasdar M, Hugh JC: The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer. 2001, 91: 1973-82. 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A
Brockhausen I, Yang JM, Burchell J, Whitehouse C, Taylor-Papadimitriou J: Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem. 1995, 233 (2): 607-17. 10.1111/j.1432-1033.1995.607_2.x
Levitin F, Stern O, Weiss M, Gil-Henn C, Ziv R, Prokocimer Z, Smorodinsky NI, Rubinstein DB, Wreschner DH: The MUC1 SEA module is a self-cleaving domain. J Biol Chem. 2005, 280: 33374-86. 10.1074/jbc.M506047200
Macao B, Johansson DG, Hansson GC, Hard T: Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin. Nat Struct Mol Biol. 2006, 13: 71-6. 10.1038/nsmb1035
Carson DD: The cytoplasmic tail of MUC1: a very busy place. Sci Signal. 2008, 1: 35-
Yang N, Wang X, Jiang J, Frank SJ: Role of the growth hormone (GH) receptor transmembrane domain in receptor predimerization and GH-induced activation. Mol Endocrinol. 2007, 12 (9): 814-21.
Thelen M, Muñoz LM, Rodríguez-Frade JM, Mellado M: Chemokine receptor oligomerization: functional considerations. Curr Opin Phamacol. 2010, 1: 38-43.
Zhang Y, Jiang J, Kopchick JJ, Frank SJ: Disulfide linkage of growth hormone (GH) receptors (GHR) reflects GH-induced GHR dimerization. Association of JAK2 with the GHR is enhanced by receptor dimerization. J Biol Chem. 1999, 274: 33072-84. 10.1074/jbc.274.46.33072
Goldsmith JF, Lee SJ, Jiang J, Frank SJ: Growth hormone induces detergent insolubility of GH receptors in IM-9 cells. Am J Physiol. 1997, 273: 932-41.
Zhang Y, Guan R, Jiang J, Frank SJ: Growth hormone (GH)-induced dimerization inhibits phorbol ester-stimulated GH receptor proteolysis. J Biol Chem. 2001, 276: 24565-73. 10.1074/jbc.M101281200
Leng Y, Cao C, Ren J, Huang L, Chen D, Ito M, Kufe D: Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem. 2007, 282: 19321-30. 10.1074/jbc.M703222200
Raina D, Ahmad R, Joshi MD, Yin L, Wu Z, Kawano T, Vasir B, Avigan D, Kharbanda S, Kufe D: Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 2009, 69: 5133-41.
Croce MV, Isla-Larrain M, Remes-Lenicov F, Colussi AG, Lacunza E, Kim KC, Gendler SJ, Segal-Eiras A: MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue. Histol Histopathol. 2006, 21 (8): 849-55.
Meerzaman D, Xing PX, Kim KC: Construction and characterization of a chimeric receptor containing the cytoplasmic domain of MUC1 mucin. Am J Physiol Lung Cell Mol Physiol. 2001, 278 (3): 625-9.
Yin L, Huang L, Kufe D: MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem. 2004, 279 (44): 45721-7. 10.1074/jbc.M408027200
Yin L, Li Y, Ren J, Kuwahara H, Kufe D: Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem. 2003, 278 (37): 35458-64. 10.1074/jbc.M301987200
Whitney ML, Otto KG, Blau CA, Reinecke H, Murry CE: Control of myoblast proliferation with a synthetic ligand. J Biol Chem. 2001, 276 (44): 41191-6. 10.1074/jbc.M103191200
Song GJ, Hinkle PM: Regulated dimerization of the thyrotropin-releasing hormone receptor affects receptor trafficking but not signaling. Mol Endocrinol. 2005, 19 (11): 2859-70. 10.1210/me.2005-0133
Parnes JR: Molecular biology and function of CD4 and CD8. Adv Immunol. 1989, 44: 265-311.
Boirsier JP, Alcover A, Herve F, Laisney I, Acuto O: Evidence for an extended structure of the T-cell coreceptor CD8α as deduced from the hydrodynamic properties of soluble forms of the extracellular region. J Biol Chem. 1993, 268: 2013-2020.
Al Masri A, Gendler SJ: Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis. Oncogene. 2005, 24 (38): 5799-808. 10.1038/sj.onc.1208738
Gao J, McConnell MJ, Yu B, Li J, Balko JM, Black EP, Johnson JO, Lloyd MC, Altiok S, Haura EB: MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol. 2009, 35 (2): 337-45.
Ogawa M, Umehara K, Yu W, Uekusa Y, Nakajima C, Tsujimura T, Kubo T, Fujiwara H, Hamaoka T: A Critical Role for a Peritumoral Stromal Reaction in the Induction of T-Cell Migration Responsible for Interleukin A -12-induced Tumor Regression. Cancer Res. 1999, 59: 1531-1538.
van de Stolpe A, van der Saag PT: Intercellular adhesion molecule-1. J Mol Med. 1996, 74 (1): 13-33. 10.1007/BF00202069
Shalloway D, Coussens PM, Yaciuk P: Overexpression of the c-src protein does not induce transformation of NIH 3T3 cells. Proc Natl Acad Sci USA. 1984, 81: 7071-5. 10.1073/pnas.81.22.7071
Hiscox S, Morgan L, Green T, Nicholson RI: Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer. 2006, 13: 53-9. 10.1677/erc.1.01297
Gonzalez L, Agullo-Ortuno MT, Garcia-Martinez JM, Calcabrini A, Gamallo C, Palacios J, Aranda A, Martín-Pérez J: Role of c-Src in human MCF7 breast cancer cell tumorigenesis. J Biol Chem. 2006, 281: 20851-64. 10.1074/jbc.M601570200
Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI: Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat. 2006, 97: 263-74. 10.1007/s10549-005-9120-9
Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA: A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res. 2007, 67: 1580-8. 10.1158/0008-5472.CAN-06-2027
Hiscox S, Jordan NJ, Smith C, James M, Morgan L, Taylor K, Green TP, Nicholson RI: Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res Treat. 2009, 115: 57-67. 10.1007/s10549-008-0058-6
Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F, Jove R: SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther. 2008, 7: 1185-94. 10.1158/1535-7163.MCT-08-0126
Hanson JM, BroweIl DA, Cunliffe WJ, Varma J, Allen A, Hemming D, Shenton BK, Young JR, Higgs MJ, Brotherick I, Pearson JP: MUC1 expression in primary breast cancer: the effect of tamoxifen treatment. Breast Cancer Res Treat. 2001, 67: 215-22. 10.1023/A:1017955726902
Paszkiewicz-Gadek A, Porowska H, Anchim T, Wolczski S, Gindzienski A: Biosynthesis of MUC1 mucin in human endometrial adenocarcinoma is modulated by estradiol and tamoxifen. Gynecol Endocrinol. 2003, 17: 37-44.
Yuan Z, Wong S, Borrelli A, Chung MA: Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochemical and Biophysical Research Communications. 2007, 362 (3): 740-6. 10.1016/j.bbrc.2007.08.074
Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT, Edwards DP: Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell. 2001, 8: 269-80. 10.1016/S1097-2765(01)00304-5
Mahanta S, Fessler SP, Park J, Bamdad C: A minimal fragment of MUC1 mediates growth of cancer cells. PLoS One. 2008, 3 (4): 2054 10.1371/journal.pone.0002054
Leichert LI, Linke K: Protein thiol modifications visualized in vivo. PLoS Biol. 2004, 2 (11): 333 10.1371/journal.pbio.0020333
Linke K, Jakob U: Not every disulfide lasts forever: disulfide bond formation as a redox switch. Antiox and Redox Signal. 2003, 5 (4): 425-434. 10.1089/152308603768295168
Dent P, Curiel DT, Fisher PB, Grant S: Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist Update. 2009, 12 (3): 65-73. 10.1016/j.drup.2009.03.001
Bristol-Myers Squib: Synopsis: Final Clinical Study Report for CA180003. 2007http://ctr.bms.com/pdf/CA180003.pdf
Schenone S, Brullo C, Musumeci F, Botta M: Novel dual Src/Abl inhibitors for hematologic and solid malignancies. Expert Opin Investig Drugs. 2010, 19 (8): 931-45. 10.1517/13543784.2010.499898
Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, Nevins JR: A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA. 2010, 107 (15): 6994-9. 10.1073/pnas.0912708107
We thank Drs. Sandra Gendler, Ken Dimock, K. Chul Kim, and ARIAD Pharmaceuticals http://www.ariad.com/regulationkits for sharing their antibodies, plasmids, cell lines, and reagents, and Maxine Farr-Jones for excellent technical support. Grant support for AB, JZ, and JH: Breast Cancer Society of Canada, Canadian Breast Cancer Research Alliance, Canadian Breast Cancer Foundation; for AS: Canadian Breast Cancer Foundation, Alberta Cancer Research Institute. AB is supported by a Pre-Doctoral Traineeship award from the US Department of Defence - Congressionally Directed Medical Research Program.
The authors declare that they have no competing interests.
AB contributed to study design, performed all experiments, analyzed data, contributed to data interpretation, and drafted the manuscript. JZ contributed to study design and constructed plasmids. EL contributed the MUC1/CD8 plasmid and contributed to data interpretation. AS contributed to study design and data interpretation. NG performed complimentary studies that aided in the interpretation of this data. JH conceived the study, contributed to study design, and helped to draft and edit the manuscript. All authors read and approved the final manuscript.
Electronic supplementary material
Additional file 1:Densitometry of Src and SrcP416 bands from SDS-PAGE (Figure6) normalized to MUC1-CD. Using ImageJ software (NIH), the Src and Src P416 bands were analyzed for densitometric intensity, and values were normalized to the intensity of the corresponding MUC1-CD band to control for protein loading. The values were then graphed versus treatment and dose for each cell line. (TIFF 83 KB)
Additional file 2:Growth curve of MUC1-CFP-Fv cells after treatment with AP20187D or AP21998M. Using Trypan blue exclusion assay, the number of live cells in a sample were counted daily for 3 days. The number of live cells in the sample was then extrapolated to estimate live cells in the population. No significant difference was found in the populations treated with AP21087D, AP21998M, or no treatment control. (TIFF 42 KB)
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.